Earlier Ovary Removal Better for BRCA Carriers

Share this content:
Earlier Ovary Removal Better for BRCA Carriers
Earlier Ovary Removal Better for BRCA Carriers

(HealthDay News) — Among women with mutations in BRCA1 or BRCA2, oophorectomy reduces the risk of developing ovarian, fallopian tube, or peritoneal cancer by 80% and reduces the risk of death by 77%, with greater BRCA1 benefit seen with earlier removal, according to a study published online Feb. 24 in the Journal of Clinical Oncology.

Amy P.M. Finch, PhD, from the University of Toronto, and colleagues examined the association between prophylactic oophorectomy and mortality in 5,783 women with mutations in BRCA1 or BRCA2. Of these, 2,270 did not have an oophorectomy, 2,123 had an oophorectomy at baseline, and 1,390 had an oophorectomy during follow-up.

RELATED: Oophorectomy as Risk Reduction Strategy for BRCA Carriers

During an average follow-up period of 5.6 years, the researchers found that 186 women were diagnosed with ovarian, fallopian tube, or peritoneal cancer, and 68 deaths were noted.

Women who underwent a bilateral oophorectomy had a significantly lower risk of developing any of these cancers (hazard ratio [HR], 0.20). Among those with no cancer at baseline, those who underwent oophorectomy also had a significantly lower risk of all-cause mortality until 70 years of age (HR, 0.23).

RELATED: Gynecologic Cancers Resource Center

The researchers noted that the prevalence of occult cancers rose sharply among BRCA1 carriers starting at 40 years of age, while no association was found for BRCA2, supporting "the recommendation for a BRCA1 mutation carrier to undergo oophorectomy at age 35 years."

"Preventive oophorectomy was associated with an 80% reduction in the risk of ovarian, fallopian tube, or peritoneal cancer in BRCA1 or BRCA2 carriers and a 77% reduction in all-cause mortality," Finch and colleagues concluded.

References

  1. Finch APM, Lubinski J, Møller P, et al. Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation. J Clin Oncol. 2014; doi:10.1200/JCO.2013.53.2820.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs